<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645305</url>
  </required_header>
  <id_info>
    <org_study_id>2555/QD-BYT</org_study_id>
    <nct_id>NCT02645305</nct_id>
  </id_info>
  <brief_title>Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Evaluation of Safety and Efficacy of Autologous Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Science Ho Chi Minh City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Van Hanh General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nguyen Tri Phuong Hospital, Ho Chi Minh city, Viet Nam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GeneWorld Ltd Co, Ho Chi Minh city, Viet Nam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Science Ho Chi Minh City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is the name for a collection of lung diseases&#xD;
      including chronic bronchitis, emphysema and chronic obstructive airways disease. People with&#xD;
      COPD have difficulties breathing, primarily due to the narrowing of their airways, this is&#xD;
      called airflow obstruction.&#xD;
&#xD;
      Some preclinical evaluations showed that COPD is closely related to chronic inflammation;&#xD;
      therefore, this study aimed to use adipose-derived stem cells (ADSCs) in the form of&#xD;
      non-expanded culture - that usually names as a stromal vascular fraction (SVF) in combination&#xD;
      with activated platelet rich plasma (PRP) to treat this disease. Both SVF and PRP are&#xD;
      autologous sources that obtained from adipose tissue and peripheral blood, respectively. This&#xD;
      mixture is intravenously transfused into the patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SGOT</measure>
    <time_frame>1 month</time_frame>
    <description>The blood SGOT levels are thus elevated with liver damage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SGPT</measure>
    <time_frame>1 month</time_frame>
    <description>The blood SGPT levels are thus elevated with liver damage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiration rate</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 min walk test</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rates of panic attacks</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP concentration</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>The CRP concentration in the patients were evaluated before and after treatment for 6 and 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adipose derived stem cells</intervention_name>
    <description>Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Adipose derived stem cells and platelet rich plasma</other_name>
    <other_name>ADSC and PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40 to 80, inclusive&#xD;
&#xD;
          -  A prior diagnosis of moderate to severe COPD&#xD;
&#xD;
          -  GOLD IIa, III, IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Life expectancy &lt; 6 months due to concomitant illnesses.&#xD;
&#xD;
          -  Exposure to any investigational drug or procedure within 1 month prior to study entry&#xD;
             or enrolled in a concurrent study that may confound results of this study.&#xD;
&#xD;
          -  Any illness which, in the Investigators judgment, will interfere with the patient's&#xD;
             ability to comply with the protocol, compromise patient safety, or interfere with the&#xD;
             interpretation of study results&#xD;
&#xD;
          -  Subjects on chronic immunosuppressive or chemotherapeutic therapy&#xD;
&#xD;
          -  Known drug or alcohol dependence or any other factors which will interfere with the&#xD;
             study conduct or interpretation of the results or who in the opinion of the&#xD;
             investigator are not suitable to participate.&#xD;
&#xD;
          -  Subjects with Alpha-1 antitrypsin deficiency (an inherited disorder that can cause&#xD;
             lung disease and liver disease).&#xD;
&#xD;
          -  Unwilling and/or not able to give written consent&#xD;
&#xD;
          -  Patient is positive for hepatitis (past history of Hepatitis A is allowed)&#xD;
&#xD;
          -  Any medical condition, which in the opinion of the clinical investigator, would&#xD;
             interfere with the treatment or outcome of the patient&#xD;
&#xD;
          -  Cerebral aneurysm clips&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Van Hanh Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Le Thi Bich, MSc., MD</last_name>
      <email>drbichphuong@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Phuong Le Thi Bich, MSc., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien Vo Duc, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University, Ho Chi Minh</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuc V Pham, PhD</last_name>
      <phone>+84903870153</phone>
      <email>pvphuc@hcmuns.edu.vn</email>
    </contact>
    <investigator>
      <last_name>Phuc V Pham, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nguyen Tri Phuong Hospital</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien Vo Duc, MD.</last_name>
      <email>myhanhchien@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Science Ho Chi Minh City</investigator_affiliation>
    <investigator_full_name>Phuc Van Pham</investigator_full_name>
    <investigator_title>MSc, PhD.</investigator_title>
  </responsible_party>
  <keyword>Safety and Efficacy</keyword>
  <keyword>Adipose stem cells</keyword>
  <keyword>Stem Cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

